'Real‐World' Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States
Autor: | Won Chan Lee, Hsiao D. Lieu, Mark B. Effron, Jingsong Lu, Yajun Zhu, Mitch DeKoven, Swapna Karkare, Cynthia Larmore, Cliff Molife, George W. Vetrovec |
---|---|
Rok vydání: | 2015 |
Předmět: |
Male
Ticagrelor Adenosine Time Factors Prasugrel Databases Factual medicine.medical_treatment Comorbidity 030204 cardiovascular system & hematology law.invention 0302 clinical medicine Randomized controlled trial Risk Factors law Odds Ratio 030212 general & internal medicine Myocardial infarction Practice Patterns Physicians' Age Factors General Medicine Middle Aged Clopidogrel Hospitalization Treatment Outcome Cardiology Female Cardiology and Cardiovascular Medicine medicine.drug Acute coronary syndrome medicine.medical_specialty Hemorrhage 03 medical and health sciences Percutaneous Coronary Intervention Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Acute Coronary Syndrome Propensity Score Aged Retrospective Studies Chi-Square Distribution business.industry Percutaneous coronary intervention medicine.disease United States business Prasugrel Hydrochloride Platelet Aggregation Inhibitors Mace |
Zdroj: | Catheterization and Cardiovascular Interventions. 88:535-544 |
ISSN: | 1522-726X 1522-1946 |
Popis: | Objectives: The 30-day clinical outcomes with prasugrel or ticagrelor were comparedusing a US payer database in patients with acute coronary syndrome (ACS) undergoingpercutaneous coronary intervention (PCI).Background: Prasugrel and ticagrelor dem-onstrated superior efficacy with increased non-coronary artery bypass graft majorbleeding compared with clopidogrel in randomized clinical trials. No direct randomizedor observational studies have compared clinical outcomes between prasugrel and tica-grelor.Methods: Patients hospitalized for ACS-PCI between August 1, 2011 and April30, 2013 and prescribed prasugrel or ticagrelor were selected. Drug treatment cohortswere propensity matched based upon demographic and clinical characteristics. Theprimary objective compared 30-day net adverse clinical events (NACE) in prasugrel-and ticagrelor-treated patients using a prespecified 20% noninferiority margin. Second-ary objectives included comparisons of major adverse cardiovascular events (MACE)and major bleeding.Results: Data were available for 16,098 patients (prasugrel,n513,134; ticagrelor,n52,964). In unmatched cohorts, prasugrel-treated patients wereyounger with fewer comorbidities than ticagrelor-treated patients, and 30-day NACE rateswere 5.6 and 9.3%, respectively (P |
Databáze: | OpenAIRE |
Externí odkaz: |